Bremelanotide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Osborn named the other specimen Dynamosaurus imperiosus in a paper in 1905. In 1906, Osborn recognized that the two skeletons were from the same species and selected Tyrannosaurus as the preferred name. In 1941, the T. rex type specimen was sold to the Carnegie Museum of Natural History in Pittsburgh, Pennsylvania, for $7,000 (equivalent to $153,224 in 2025). The original Dynamosaurus material now resides in the collections of the Natural History Museum, London. From the 1910s through the end of the 1950s, Barnum's discoveries remained the only specimens of Tyrannosaurus, as the Great Depression and wars kept many paleontologists out of the field.
Chronic constipation is especially common, and is thought to be aggravated by an asymmetric pelvis (acetabular protrusion). Especially in childhood, OI-associated constipation may cause a feeling of fullness and associated food refusal, leading to malnutrition.
Vitamin or hormone supplements for what the body is lacking due to the disease (insulin, vitamin B12, thyroid hormone, etc.) Blood transfusions if the disease is blood related Physical therapy if the disease impacts bones, joints, or muscles Pharmaceutical treatment options include immunosuppressant drugs to reduce the immune response against the body's own tissues, such as:
=== Stiffness and elasticity === The ECM can exist in varying degrees of stiffness and elasticity, from soft brain tissues to hard bone tissues. The elasticity of the ECM can differ by several orders of magnitude. This property is primarily dependent on collagen and elastin concentrations, and it has recently been shown to play an influential role in regulating numerous cell functions. Cells can sense the mechanical properties of their environment by applying forces and measuring the resulting backlash. This plays an important role because it helps regulate many important cellular processes including cellular contraction, cell migration, cell proliferation, differentiation and cell death (apoptosis). Inhibition of nonmuscle myosin II blocks most of these effects, indicating that they are indeed tied to sensing the mechanical properties of the ECM, which has become a new focus in research during the past decade.
=== Radioactivity === Thorium was first observed to be radioactive in 1898, by the German chemist Gerhard Carl Schmidt and later that year, independently, by the Polish-French physicist Marie Curie. It was the second element that was found to be radioactive, after the 1896 discovery of radioactivity in uranium by French physicist Henri Becquerel. Starting from 1899, the New Zealand physicist Ernest Rutherford and the American electrical engineer Robert Bowie Owens studied the radiation from thorium; initial observations showed that it varied significantly. It was determined that these variations came from a short-lived gaseous daughter of thorium, which they found to be a new element. This element is now named radon, the only one of the rare radioelements to be discovered in nature as a daughter of thorium rather than uranium. After accounting for the contribution of radon, Rutherford, now working with the British physicist Frederick Soddy, showed how thorium decayed at a fixed rate over time into a series of other elements in work dating from 1900 to 1903. This observation led to the identification of the half-life as one of the outcomes of the alpha particle experiments that led to the disintegration theory of radioactivity. The biological effect of radiation was discovered in 1903. The newly discovered phenomenon of radioactivity excited scientists and the general public alike. In the 1920s, thorium's radioactivity was promoted as a cure for rheumatism, diabetes, and sexual impotence.
Sources: en.wikipedia.org
== Approval == Pramlintide has been approved on 3/16/2005 by the FDA, for use by type 1 and type 2 diabetic patients who use insulin.(subscription required) Pramlintide allows patients to use less insulin, lowers average blood sugar levels, and substantially reduces what otherwise would be a large unhealthy rise in blood sugar that occurs in diabetics right after eating. Apart from insulin analogs, pramlintide is the only drug approved by the FDA to lower blood sugar in type 1 diabetics since insulin in the early 1920s.
On September 26, 2020, an event was held in the White House Rose Garden announcing Amy Coney Barrett's nomination to the Supreme Court following the death of Ruth Bader Ginsburg. According to a 2021 book by Trump's Chief of Staff Mark Meadows, hours after the ceremony, Trump tested positive for COVID-19, although a subsequent test returned negative. Meadows recalled that Trump looked "a little tired" and was suspected of having a "slight cold". Trump later traveled in Air Force One to a rally at the Harrisburg International Airport in Pennsylvania, which was attended by thousands. After Trump's diagnosis was made public, Pennsylvania health officials advised attendees to participate in the state's contact tracing program. After returning from Bedminster, Trump received a positive test result on a rapid test and was waiting to get results of a PCR test when he did a live phone interview on Hannity. On October 2, 2020, Trump tweeted that he and his wife Melania Trump had both tested positive for COVID-19, part of a White House outbreak. Later that day, Trump was hospitalized at Walter Reed National Military Medical Center, reportedly due to fever and labored breathing. He was treated with antivirals, an experimental antibody drug (REGN-COV2), and a steroid. He returned to the White House on October 5, still infectious and unwell. In 2021, it was revealed that his condition had been far more serious than he had previously indicated; he had dangerously low blood oxygen levels, a high fever, and lung infiltrates, indicating a severe case of COVID-19.
CRC Press, 2001 Tracy, Douglas S.; Nash, Robert A., "A Validation Approach for Laboratory Information Management Systems", Journal of Validation Technology, 2002, 9(1), 6-14 Perry, Douglas, "Laboratory Informatics: Origin, Scope, and its Place in Higher Education", Journal of the Association for Laboratory Automation, 2004, 9(6), 421 - 428 Sterling, James D., "Laboratory Automation Education", Journal of the Association for Laboratory Automation, 2004, 9(5), A11-A12 Sterling, James D., "Laboratory automation curriculum at Keck Graduate Institute", Journal of the Association for Laboratory Automation, 2004, 9(5), 331-335 Taylor, Keith, "The status of electronic laboratory notebooks for chemistry and biology", Current Opinion in Drug Discovery & Development, 2006, 9(3): 348-353 Wood, Simon, "Comprehensive Laboratory Informatics: A Multilayer Approach", American Laboratory, 2007, 39(16), 20-23 Metrick, Gloria, "Three Issues of LIMS/Laboratory Informatics That Can Cost Money", American Laboratory, 2007, 39(21), 10-11 Calva, Diana; Lehman, Mario, "An analysis of the possible applications of Artificial Intelligence Techniques to a Clinical Laboratory Information Management System", International Journal of Computer Science and Network Security, 2008, 8(12), 82-86 Shah, Kim, "Elevating laboratory informatics to assist decision-making", Pharmaceutical Technology Europe, 2009, 21(5)
== External links == Equianalgesic Charts American Pain Society Guidelines Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain Online opioid equianalgesia calculator Electronic calculator that includes logic for bidirectional and dose-dependent conversions Shaheen, PE; Walsh, D; Lasheen, W; Davis, MP; Lagman, RL (2009). "Opioid equianalgesic tables: are they all equally dangerous?". J Pain Symptom Manage. 38 (3): 409–17. doi:10.1016/j.jpainsymman.2009.06.004. PMID 19735901.
Sources: en.wikipedia.org
These kilns can be the fastest to dry and most efficient with energy usage. In a vacuum, water boils at a lower temperature. In addition to increased speed, a vacuum kiln can also produce an improved quality in the wood. Low ambient pressure does lower the boiling point of water but the amount of energy required to convert the liquid to vapor is the same. Savings come from not being required to heat a huge building and not being required to vent the heat while lowering humidity. Since all free water can be removed at below 115 °F, quality is improved. While conventional drying uses warm, dry air to skim water off the surface, vacuum kilns can boil water from within the wood. This enables a good vacuum kiln to dry very thick wood very quickly. It is possible to dry 12/4 Red Oak fresh off the saw to 7% in 11 days. Since wood is dried with a vapor gradient - vapor pressure to ambient pressure - humidity can be kept very high. Because of this, a good vacuum kiln can dry 4.5" thick White Oak fresh off the saw to 8% in less than a month, a feat that was previously thought to be impossible.
During total overcast, the amount of absorption due to clouds is heavily dependent on the thickness of the clouds and latitude, with no clear measurements correlating specific thickness and absorption of UVA and UVB. The shorter bands of UVC, as well as even more-energetic UV radiation produced by the Sun, are absorbed by oxygen and generate the ozone in the ozone layer when single oxygen atoms produced by UV photolysis of dioxygen react with more dioxygen. The ozone layer is especially important in blocking most UVB and the remaining part of UVC not already blocked by ordinary oxygen in air.
=== Neural sources === In the hypothalamus, oxytocin is made in magnocellular neurosecretory cells of the supraoptic and paraventricular nuclei, and is stored in Herring bodies at the axon terminals in the posterior pituitary. It is then released into the blood from the posterior lobe (neurohypophysis) of the pituitary gland. These axons (likely, but dendrites have not been ruled out) have collaterals that innervate neurons in the nucleus accumbens, a brain structure where oxytocin receptors are expressed. The endocrine effects of hormonal oxytocin, and the cognitive or behavioral effects of oxytocin neuropeptides are thought to be coordinated through its common release through these collaterals. Oxytocin is also produced by some neurons in the paraventricular nucleus that project to other parts of the brain and to the spinal cord. Depending on the species, oxytocin receptor-expressing cells are located in other areas, including the amygdala and bed nucleus of the stria terminalis. In the pituitary gland, oxytocin is packaged in large, dense-core vesicles, where it is bound to neurophysin I as shown in the inset of the figure; neurophysin is a large peptide fragment of the larger precursor protein molecule from which oxytocin is derived by enzymatic cleavage. The electrical activity of the oxytocin cells in the hypothalamus regulates the secretion of oxytocin from the neurosecretory nerve endings.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.